MX386642B - Preparación y composiciones de azufre con valencia cero, altamente bio-disponibles, y sus usos. - Google Patents
Preparación y composiciones de azufre con valencia cero, altamente bio-disponibles, y sus usos.Info
- Publication number
- MX386642B MX386642B MX2018012760A MX2018012760A MX386642B MX 386642 B MX386642 B MX 386642B MX 2018012760 A MX2018012760 A MX 2018012760A MX 2018012760 A MX2018012760 A MX 2018012760A MX 386642 B MX386642 B MX 386642B
- Authority
- MX
- Mexico
- Prior art keywords
- compositions
- preparation
- zero valence
- sulphur
- available sulfur
- Prior art date
Links
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 title abstract 4
- 239000000203 mixture Substances 0.000 title abstract 4
- 238000002360 preparation method Methods 0.000 title abstract 2
- 229910052717 sulfur Inorganic materials 0.000 title 1
- 239000011593 sulfur Substances 0.000 title 1
- 239000005864 Sulphur Substances 0.000 abstract 3
- RWSOTUBLDIXVET-UHFFFAOYSA-N Dihydrogen sulfide Chemical compound S RWSOTUBLDIXVET-UHFFFAOYSA-N 0.000 abstract 1
- 239000000729 antidote Substances 0.000 abstract 1
- 229940075522 antidotes Drugs 0.000 abstract 1
- 235000013305 food Nutrition 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 230000036542 oxidative stress Effects 0.000 abstract 1
- 230000001575 pathological effect Effects 0.000 abstract 1
- 229940002612 prodrug Drugs 0.000 abstract 1
- 239000000651 prodrug Substances 0.000 abstract 1
- 230000001737 promoting effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/04—Sulfur, selenium or tellurium; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/04—Drugs for disorders of the respiratory system for throat disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/08—Antiseborrheics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/12—Ophthalmic agents for cataracts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/02—Nutrients, e.g. vitamins, minerals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/06—Free radical scavengers or antioxidants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Virology (AREA)
- Cardiology (AREA)
- Diabetes (AREA)
- Heart & Thoracic Surgery (AREA)
- Epidemiology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Dermatology (AREA)
- Hematology (AREA)
- Inorganic Chemistry (AREA)
- Neurology (AREA)
- Pulmonology (AREA)
- Molecular Biology (AREA)
- Obesity (AREA)
- Ophthalmology & Optometry (AREA)
- Neurosurgery (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Psychiatry (AREA)
- Urology & Nephrology (AREA)
- Toxicology (AREA)
- Rheumatology (AREA)
- Hospice & Palliative Care (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
Abstract
La presente invención presenta composiciones ricas en azufre y preparaciones de las mismas que son seguras y efectivas como pro-fármacos de sulfuro de hidrógeno de alta bio-disponibilidad. La invención también incluye métodos para tratar condiciones patológicas asociadas con estrés oxidativo usando composiciones ricas en azufre. La invención además incluye composiciones ricas en azufre como antídotos y alimento médico para conservar y promover la salud general.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161534585P | 2011-09-14 | 2011-09-14 | |
| PCT/MX2012/000086 WO2013055199A1 (es) | 2011-09-14 | 2012-09-13 | Preparación y composiciones de azufre con valencia cero. altamente biq-disponibles y sus usos |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX386642B true MX386642B (es) | 2025-03-19 |
Family
ID=47830038
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2014003289A MX360050B (es) | 2011-09-14 | 2012-09-13 | Preparacion y composiciones de azufre con valencia cero, altamente bio-disponibles, y sus usos. |
| MX2018012760A MX386642B (es) | 2011-09-14 | 2012-09-13 | Preparación y composiciones de azufre con valencia cero, altamente bio-disponibles, y sus usos. |
| MX2014003288A MX2014003288A (es) | 2011-09-14 | 2012-09-13 | Preparacion y composiciones de azufre con valencia cero, altamente bio-disponibles, y sus usos. |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2014003289A MX360050B (es) | 2011-09-14 | 2012-09-13 | Preparacion y composiciones de azufre con valencia cero, altamente bio-disponibles, y sus usos. |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2014003288A MX2014003288A (es) | 2011-09-14 | 2012-09-13 | Preparacion y composiciones de azufre con valencia cero, altamente bio-disponibles, y sus usos. |
Country Status (11)
| Country | Link |
|---|---|
| US (3) | US8771755B2 (es) |
| EP (2) | EP2756757B1 (es) |
| JP (2) | JP5992525B2 (es) |
| CN (2) | CN104080334A (es) |
| AU (3) | AU2012321444B2 (es) |
| BR (3) | BR112014005144B1 (es) |
| CA (2) | CA2847589C (es) |
| ES (1) | ES2739628T3 (es) |
| HK (1) | HK1200278A1 (es) |
| MX (3) | MX360050B (es) |
| WO (2) | WO2013055199A1 (es) |
Families Citing this family (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8541396B2 (en) | 2009-04-24 | 2013-09-24 | National University Of Singapore | Morpholin-4-ium 4 methoxyphenyl (morpholino) phosphinodithioate (GYY4137) as a novel vasodilator agent |
| US9306218B2 (en) | 2011-08-11 | 2016-04-05 | Arizona Board Of Regents On Behalf Of The University Of Arizona | High sulfur content copolymers and composite materials and electrochemical cells and optical elements using them |
| US11795248B2 (en) | 2011-08-11 | 2023-10-24 | Arizona Board Of Regents On Behalf Of The University Of Arizona | Copolymerization of elemental sulfur and epoxy functional styrenics |
| US11015023B2 (en) | 2011-08-11 | 2021-05-25 | Arizona Board Of Regents On Behalf Of The University Of Arizona | Fire retardant compositions utilizing elemental sulfur |
| US10920020B2 (en) | 2011-08-11 | 2021-02-16 | Arizona Board Of Regents On Behalf Of The University Of Arizona | 3D-printing of ultra-high refractive index polymers |
| US9567439B1 (en) | 2011-08-11 | 2017-02-14 | The Arizona Board Of Regents On Behalf Of The University Of Arizona | Sulfur composites and polymeric materials from elemental sulfur |
| HK1200278A1 (en) * | 2011-09-14 | 2015-08-07 | Nuevas Alternativas Naturales, S.A.P.I. de C.V. | Preparation and compositions of highly bioavailable zerovalent sulfur and uses thereof |
| US10894863B2 (en) | 2014-02-14 | 2021-01-19 | Arizona Board Of Regents On Behalf Of The University Of Arizona | Cathode materials for Li—S batteries |
| KR20160122838A (ko) * | 2014-02-14 | 2016-10-24 | 더 아리조나 보드 오브 리전츠 온 비해프 오브 더 유니버시티 오브 아리조나 | 원소 황에서 유래된 황 복합체 및 폴리머 재료 |
| US9795676B2 (en) | 2014-03-03 | 2017-10-24 | Shayne Kenneth Morris | Chromium 4-hydroxyisoleucinate compound methods for prepartion and use |
| EP3151671A4 (en) * | 2014-06-03 | 2018-03-07 | Sulfagenix, Inc. | Methods and compositions for treating nitric oxide deficiency disorders and related conditions |
| JP6806965B2 (ja) * | 2014-07-29 | 2021-01-06 | 国立大学法人 筑波大学 | 精子機能改善剤とこれを含む医薬品組成物、飼料、食品組成物及び家畜または家禽の精子機能改善方法 |
| WO2016159612A1 (ko) * | 2015-03-27 | 2016-10-06 | 서울대학교산학협력단 | 폴리설파이드 공중합체 나노입자 및 그의 제조 방법 |
| US11078333B2 (en) | 2015-07-13 | 2021-08-03 | Arizona Board Of Regents On Behalf Of The University Of Arizona | Copolymerization of elemental sulfur to synthesize high sulfur content polymeric materials |
| US10238685B2 (en) * | 2015-12-02 | 2019-03-26 | Johnson & Johnson Consumer Inc. | Compositions containing polymeric sulfur and uses thereof |
| US20170252369A1 (en) * | 2016-03-03 | 2017-09-07 | Frederick J. Sawaya | Method for treating parkinson disease, neurodegenerative disorders, and autoimmune diseases |
| CN107281215A (zh) * | 2016-04-01 | 2017-10-24 | 复旦大学附属妇产科医院 | 硫化氢供体硫氢化钠在制药中的用途 |
| WO2018107169A1 (en) | 2016-12-09 | 2018-06-14 | Arizona Board Of Regents On Behalf Of The University Of Arizona | Metallopolymers for catalytic generation of hydrogen |
| JP6989157B2 (ja) * | 2017-02-09 | 2022-01-05 | ノクサノ インコーポレイテッド | 電気化学ガス状伝達物質生成組成物及びその使用方法ならびにそれを組み込んだ被覆材及び治療システム |
| US20180271823A1 (en) * | 2017-03-23 | 2018-09-27 | Washington State University | Sulfur-based broad spectrum antivirals |
| US11674005B2 (en) | 2017-06-15 | 2023-06-13 | Arizona Board Of Regents On Behalf Of The University Of Arizona | Chalcogenide Hybrid Inorganic/organic Polymer (CHIP) materials as improved crosslinking agents for vulcanization |
| FR3072024A1 (fr) * | 2017-10-11 | 2019-04-12 | Olivier Petitjean | Prevention et traitement de l’hyperplasie benigne de la prostate a l‘aide d’un inhibiteur selectif de la production d’especes reactives de l’oxygene d’origine mitochondriale |
| CN108486081B (zh) * | 2018-05-04 | 2021-07-02 | 山西大学 | 一种植物巯基丙酮酸硫转移酶及其应用 |
| WO2020046635A1 (en) * | 2018-08-28 | 2020-03-05 | The Regents Of The University Of California | Tetrathionate for cyanide and methylmercaptan poisoning |
| WO2021092392A1 (en) * | 2019-11-07 | 2021-05-14 | Cornell University | Use of membrane inhibitors to enhance vaccine development against enveloped viruses |
| WO2021226037A1 (en) * | 2020-05-04 | 2021-11-11 | Sulfagenix, Inc. | Treatment of viral infections |
| FR3125409A1 (fr) * | 2021-07-26 | 2023-01-27 | Nuribiol | Complément alimentaire permettant de lutter contre l’infertilité féminine et masculine |
| IT202100021548A1 (it) * | 2021-08-09 | 2023-02-09 | Universita’ Di Pisa | Coniugati della metformina e loro impiego terapeutico |
| WO2023079466A2 (en) * | 2021-11-03 | 2023-05-11 | Sulfagenix, Inc. | Treatment of sequelae of coronavirus infections |
| EP4212149A1 (en) | 2022-01-18 | 2023-07-19 | Rijksuniversiteit Groningen | Oral dosage forms of acid-labile salt and methods and uses related thereto |
| WO2024127426A1 (en) * | 2022-12-12 | 2024-06-20 | Polishetty Ravishankar | An herbal formulation prs-01 for regeneration of the cardiomyocytes |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IT1213050B (it) * | 1986-03-14 | 1989-12-07 | Schiena Ricerche | Composizioni farmaceutiche topiche in odontostomatologia contenenti allantoina e zolfo elementare |
| US5100653A (en) * | 1991-02-08 | 1992-03-31 | Giovanni Campo | Topical compositions for treating mouth tissues |
| US6855342B2 (en) * | 2000-06-30 | 2005-02-15 | Medicis Pharmaceutical Corporation | Compositions and methods for high sorption of skin materials and delivery of sulfur |
| US6514489B1 (en) * | 2000-06-30 | 2003-02-04 | Medicis Pharmaceutical Corp. | Sulfur containing dermatological compositions and methods for reducing malodors in dermatological compositions |
| AUPS255402A0 (en) * | 2002-05-27 | 2002-06-13 | Monash University | Agents and methods for the treatment of disorders associated with oxidative stress |
| US8361514B2 (en) * | 2002-06-19 | 2013-01-29 | Nuevas Alternatives Naturales Thermafat, S.A.P.I. de C.V. | Systemic treatment of pathological conditions resulting from oxidative stress and/or redox imbalance |
| US20030235571A1 (en) | 2002-06-19 | 2003-12-25 | Gabriel Gojon-Romanillos | Systemic treatment of pathological conditions resulting from oxidative stress and/or redox imbalance |
| CN1320925C (zh) * | 2005-03-30 | 2007-06-13 | 淮北市辉克药业有限公司 | 长期使用的治疗糖尿病的复方制剂 |
| US7741359B2 (en) | 2005-05-27 | 2010-06-22 | Antibe Therapeutics Inc. | Hydrogen sulfide derivatives of non-steroidal anti-inflammatory drugs |
| US20100172992A1 (en) * | 2006-06-02 | 2010-07-08 | Natural Ma Inc. | Pathogenic attenuation via the administration of an equilibiotic compound |
| US7923037B2 (en) | 2006-10-05 | 2011-04-12 | Ikaria, Inc. | Liquid chalcogenide compositions and methods of manufacturing and using the same |
| US20120135091A1 (en) * | 2007-01-18 | 2012-05-31 | Roth Mark B | Methods and compositions for enhancing lifespan involving sirtuin-modulating compounds and chalcogenides |
| EP2170356A1 (en) * | 2007-06-25 | 2010-04-07 | Fred Hutchinson Cancer Research Center | Methods and compositions regarding polychalcogenide compositions |
| EP2167068A2 (en) | 2007-07-05 | 2010-03-31 | Inserm-Institut National De La Sante Et De La Recherche Medicale | Anticonvulsive pharmaceutical compositions |
| CN101467991B (zh) * | 2007-08-02 | 2012-02-01 | 复旦大学 | 烯丙基半胱氨酸及其类似物在制备治疗心肌损伤药物中的用途 |
| US20110172171A1 (en) | 2008-09-12 | 2011-07-14 | Serge Picaud | Taurine or taurine-like substances for the prevention of brain oedema |
| RU2406477C1 (ru) | 2009-08-25 | 2010-12-20 | Федеральное государственное учреждение "Научно-исследовательский центр курортологии и реабилитации Федерального агентства по здравоохранению и социальному развитию" (ФГУ "НИЦКиР Росздрава") | Способ лечения ишемической болезни сердца, стенокардии напряжения i-ii функциональных классов |
| US8680151B2 (en) * | 2010-02-11 | 2014-03-25 | Fred Hutchinson Cancer Research Center | Compounds, compositions and methods for treating or preventing hypoxic or ischemic injury |
| WO2012075242A2 (en) | 2010-12-01 | 2012-06-07 | Washington State University Research Foundation | Controlled chemical release of hydrogen sulfide |
| HK1200278A1 (en) * | 2011-09-14 | 2015-08-07 | Nuevas Alternativas Naturales, S.A.P.I. de C.V. | Preparation and compositions of highly bioavailable zerovalent sulfur and uses thereof |
-
2012
- 2012-09-13 HK HK15100737.1A patent/HK1200278A1/xx unknown
- 2012-09-13 EP EP12840653.5A patent/EP2756757B1/en active Active
- 2012-09-13 WO PCT/MX2012/000086 patent/WO2013055199A1/es not_active Ceased
- 2012-09-13 WO PCT/US2012/055205 patent/WO2013040240A1/en not_active Ceased
- 2012-09-13 US US13/614,820 patent/US8771755B2/en active Active
- 2012-09-13 BR BR112014005144-5A patent/BR112014005144B1/pt not_active IP Right Cessation
- 2012-09-13 BR BR112014004859A patent/BR112014004859A2/pt unknown
- 2012-09-13 JP JP2014530618A patent/JP5992525B2/ja not_active Expired - Fee Related
- 2012-09-13 MX MX2014003289A patent/MX360050B/es active IP Right Grant
- 2012-09-13 ES ES12840653T patent/ES2739628T3/es active Active
- 2012-09-13 MX MX2018012760A patent/MX386642B/es unknown
- 2012-09-13 BR BR122020020392-7A patent/BR122020020392B1/pt not_active IP Right Cessation
- 2012-09-13 CA CA2847589A patent/CA2847589C/en active Active
- 2012-09-13 CN CN201280055604.5A patent/CN104080334A/zh active Pending
- 2012-09-13 AU AU2012321444A patent/AU2012321444B2/en not_active Ceased
- 2012-09-13 US US14/345,044 patent/US20150064286A1/en not_active Abandoned
- 2012-09-13 MX MX2014003288A patent/MX2014003288A/es unknown
- 2012-09-13 CA CA2847264A patent/CA2847264A1/en not_active Abandoned
- 2012-09-13 EP EP12830924.2A patent/EP2755478A4/en not_active Withdrawn
- 2012-09-13 JP JP2014530796A patent/JP2014526511A/ja active Pending
- 2012-09-13 AU AU2012308501A patent/AU2012308501A1/en not_active Abandoned
- 2012-09-13 CN CN201280055643.5A patent/CN104080339B/zh not_active Expired - Fee Related
-
2014
- 2014-04-16 US US14/254,396 patent/US20140322361A1/en not_active Abandoned
-
2015
- 2015-08-06 AU AU2015210403A patent/AU2015210403B2/en not_active Ceased
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX386642B (es) | Preparación y composiciones de azufre con valencia cero, altamente bio-disponibles, y sus usos. | |
| DOP2014000233A (es) | Compuestos de microarn y métodos de modulación de la actividad de mir-21 | |
| ECSP14017269A (es) | Compuestos para tratar la atrofia muscular espinal | |
| UY35472A (es) | Compuestos y sus usos en la modulacion de la hemoglobina | |
| MX358514B (es) | Compuestos para tratar la atrofia muscular espinal. | |
| MX378131B (es) | Compuestos y sus usos para modular la hemoglobina. | |
| MX388013B (es) | Compuestos y usos de estos para la modulación de la hemoglobina. | |
| EA201591432A1 (ru) | Соединения и их применения для модуляции гемоглобина | |
| MX2014001717A (es) | Composiciones inmunoterapeuticas de levadura-mucina 1 (muc1) y usos de las mismas. | |
| SG10201809290SA (en) | Compositions and Methods to Treating Hemoglobinopathies | |
| ECSP15019323A (es) | Derivados de 5-fluoro-n-(piridin-2-il)piridin-2-amina que contienen un grupo sulfoximina | |
| MX2014008705A (es) | Compuestos tricíclicos de sulfona y métodos para elaborarlos y utilizarlos. | |
| MX353299B (es) | Metodos y composiciones relacionadas con p62 para el tratamiento y profilaxis del cancer. | |
| CR20150067A (es) | Pirazoles sustituidos como bloqueadores del canal de calcio tipo n | |
| BR112018003745A2 (pt) | composições que compreendem um composto de urolitina | |
| GT201400066A (es) | Agentes inductores de la apoptosis que pueden usarse para tratar el cáncer y las enfermedades inmunes y autoinmunes | |
| IN2015DN03322A (es) | ||
| EA202092627A1 (ru) | Соединения и их применения для модуляции гемоглобина | |
| MX2015003701A (es) | Composiciones para tratamiento. | |
| MX373650B (es) | Triheptanoina para el tratamiento de la deficiencia del transportador de glucosa 1. | |
| CR20150070A (es) | Pirrolopirazoles como bloqueadores del canal de calcio tipo n | |
| EA201401117A1 (ru) | Композиции, содержащие пробиотики и комплекс пчелиной пыльцы/глины, способ их приготовления и их применение в питании и терапии | |
| BR112017023744A2 (pt) | método para obtenção de uma biomassa de uma microalga das espécies tetraselmis chuii enriquecidas em superóxido dismutase (sod) | |
| MX2016006544A (es) | Witanolidos utiles para el tratamiento de enfermedades neurodegenerativas. | |
| MX2018008069A (es) | Composicion lipida vegetal para promover el crecimiento del cabello, metodo para promover el crecimiento del cabello y uso de los lipidos vegetales. |